FDAapproval95% confidence
Competitive Generic Therapy Approvals
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (prostate cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Explore the FDA’s Competitive Generic Therapy Approvals page, offering insights into the program designed to encourage generic drug competition. Access information about approved CGT products and find resources, including a downloadable CGT approvals spreadsheet.
Supporting Context
- Therapeutic area
- Oncology · Prostate Cancer
- Sub-indication
- Prostate Cancer
Related signal: Roche's VENTANA PTEN Assay Receives FDA Approval for Prostate Cancer Companion Diagnostic